Skip to main content

Table 3 Use of health resources in monitoring of OAT

From: Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist

 

First year

Successive years

PSM

PCpc

Hpc

Hvp

Dabi

PSM

PCpc

Hpc

Hvp

Dabi

Health costs

N° of checkups/year

52

13

13

13

-

52

13

13

13

-

Specialist (min/control)

  

2

2

   

2

2

 

Nurse (min/control)

 

5

5

5

  

5

5

5

 

Test (venous blood/control)

   

1

    

1

 

Test (Coaguchek strips/control)

1

1

1

  

1

1

1

  

Nurse (min/training)

240

20

20

20

20

 

-

-

-

-

Non health costs

Patient timea (min/control)

5

60

120

120

-

5

60

120

120

-

Companion timea (min/control)

5

60

120

120

-

5

60

120

120

-

Patient time (min/training)

240

-

-

-

-

-

-

-

-

-

Companion time (min/training)

240

-

-

-

-

-

-

-

-

-

% of patients with companion

23.4 %

25.6 %

25.6 %

25.6 %

-

23.4 %

25.6 %

25.6 %

25.6 %

-

  1. aAssuming a mean trip of 2 km and 30 km for control in primary care and hospital, respectively
  2. PSM Patient self-management; PCpc Primary care with portable coagulometer; Hpc Hospital with portable coagulometer; Hvp Hospital with venipuncture; Dabi Dabigatran